Safety and Efficacy of Osimertinib Combined With Anlotinib in EGFRm+, Treatment-naïve IIIb/IV NSCLC Patients: a Prospective, Single Arm, Phase Ib/IIa Study
Latest Information Update: 20 Aug 2024
At a glance
- Drugs Catequentinib (Primary) ; Osimertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms AUTOMAN
- 15 Aug 2024 Status changed from recruiting to completed.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 21 Sep 2021 Results (as of 25th Apr 2021; n=12) presented at the 46th European Society for Medical Oncology Congress.